Life Sciences
environment, enabling quick entry to market for innovations and access to anonymised patient data and patients for clinical trials. Investors have the opportunity to invest in world-leading research with access to new fiscal measures to reduce costs and support risk taking. Researchers can access cutting-edge facilities,
real life data and an integrated system for bio medicine. Clinicians play an active role in innovation and research, and are better able to improve patient outcomes. Patients, meanwhile, are empowered with more choice and as a result have better access to more effective treatments. In the LSO we support overseas investment
into the UK from the earliest R&D collaborations through to clinical trials, commercial operations and partnerships. We support and promote trade opportunities alongside that of investment and recognise the need to support every component of the pathway. From bench to bedside, we are making it easier to discover, develop and deliver healthcare innovation in the UK. Businesses benefit from the opportunity to use the
UK as a launch pad to other international markets, whether in Europe or beyond. The UK’s excellent reputation in research, clinical development, health regulation, and health economics combined with UKTI’s own global connectivity mean that the UK can help businesses maximise their export and investment potential. Over my 25 years in the discovery of novel
treatments for diseases of the nervous system I have seen many changes and the UK now operates in an extremely competitive global environment. We can no longer take for granted that the UK is considered the world leader in cutting-edge clinical trials, we need to keep proving that point.
DR MARK TREHERNE
Chief Executive, UKTI Life Sciences Organisation (LSO) August 2012 - Present Mark is a research scientist with a PhD in Pharmacology from Cambridge University and has over
25 years’ industrial experience in the discovery of novel treatments for diseases of the nervous system. Formerly at Pfizer in Sandwich, UK, and responsible for research into neurodegenerative diseases before leaving Pfizer in 1997 to set up Cambridge Drug Discovery (CDD) as Chief Executive, which was sold to BioFocus in 2001. Mark has helped to raise funds for various early-stage biotechnology companies and has now served on the Boards of over 15 private and public biopharmaceutical companies around the world. Mark is Chief Executive of the LSO and leads a team of senior civil servants and sector specialists working together to support the Government’s Industrial Strategy and support overseas investment into the UK from the earliest R&D collaborations through to clinical trials, commercial operations and partnerships. The LSO team also offer trade support to exporting companies and companies seeking to export from the UK.
Life Sciences Organisation In the UK, partners work together to support a
|
research and innovation culture that spans sectors and geographies, and supports the creation of a fully integrated life science and healthcare ecosystem that places the patient at the heart of the system. Globally, there is a growing demand for stratified medicines and companion diagnostics. With first class research and expertise, world leading data & translational infrastructure and an established value chain, the UK has a great deal to offer in this space. The UK’s focus on improving the efficiency of the
translation of scientific discoveries into innovative products and services is showcased by the work of the National Institute for Health Research (NIHR). NIHR funding for providers of NHS services undertaking clinical trials now achieves a benchmark of 70 days or less from receipt of a valid research application to recruitment of the first participant. The NIHR Clinical Research Networks are embedded in the NHS supporting the delivery of multi-centre clinical studies. 630,000 patients were recruited in 2013 into clinical research studies. This has trebled since 2010. The NIHR Office for Clinical Research Infrastructure (NOCRI) helps businesses access world-class facilities, and well-characterised and diverse patient cohorts drawn from the 60 million people who use the NHS in the UK. These are just a few illustrations of how the UK provides an unrivalled ecosystem that brings together businesses, researchers, clinicians and patients to translate discovery into clinical use. The Francis Crick Institute, due to open in
2015, is testament to our world class standing. Housing over 1,250 scientists with a mission to understand why disease develops and find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease and stroke, infections, and neurodegenerative diseases it will be one of the most significant developments in UK biomedical science for a generation. A partnership between the MRC, Cancer Research UK, the Wellcome Trust, University College London, King’s College London and Imperial College London, the Institute will not only help to improve people’s lives but will also keep the UK at the forefront of innovation in medical research and importantly foster meaningful collaborations with other centres of excellence. The ecosystem is further supported by the UK
Government’s introduction of fiscal measures to stimulate innovation and growth for companies: for example the Patent Box offers a lower corporation tax of 10% on qualifying profits, and R&D tax credits for small and medium sized enterprises gives up to 33% back on spending - one of the most generous in the world - and importantly we have corporation tax falling further to 20% by 2015. It’s these types of key points and comparative
strengths of the UK life science sector that we need to keep re-affirming to deliver the UK’s long-term commitment to life sciences on a global stage.
Further information
www.lifesciences.ukti.gov.uk
global-opportunity.co.uk Issue 01 | Global Opportunity Healthcare 2015 167
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152 |
Page 153 |
Page 154 |
Page 155 |
Page 156 |
Page 157 |
Page 158 |
Page 159 |
Page 160 |
Page 161 |
Page 162 |
Page 163 |
Page 164 |
Page 165 |
Page 166 |
Page 167 |
Page 168 |
Page 169 |
Page 170 |
Page 171 |
Page 172 |
Page 173 |
Page 174 |
Page 175 |
Page 176 |
Page 177 |
Page 178 |
Page 179 |
Page 180 |
Page 181 |
Page 182 |
Page 183 |
Page 184 |
Page 185 |
Page 186 |
Page 187 |
Page 188 |
Page 189 |
Page 190 |
Page 191 |
Page 192 |
Page 193 |
Page 194 |
Page 195 |
Page 196 |
Page 197 |
Page 198 |
Page 199 |
Page 200 |
Page 201 |
Page 202 |
Page 203 |
Page 204